{"schema_version":"secwatch.filing_event.v1","accession":"0001689375-22-000043","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.714177+00:00","generated_at":"2026-06-22T05:33:45.217232+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Entrada Therapeutics reports Q3 2022 net loss of $25.1M; cash runway into H2 2024","bullets":["Cash, cash equivalents and marketable securities of $215.6M as of Sept 30, 2022, down from $291.1M at Dec 31, 2021.","Net loss for Q3 2022 was $25.1M, compared to $14.4M in Q3 2021.","R&D expenses increased to $19.0M (Q3 2022) from $10.5M (Q3 2021); G&A expenses rose to $7.0M from $3.9M.","On track to file IND for ENTR-601-44 (Duchenne exon 44 skipping) in Q4 2022; second IND for ENTR-701 (DM1) planned for H2 2023.","Preclinical data for ENTR-701 presented at World Muscle Society; collaboration entered with Myotonic Dystrophy Clinical Research Network."],"urls":{"canonical":"https://secwatch.observer/filing/0001689375-22-000043","json":"https://secwatch.observer/filing/0001689375-22-000043.json","markdown":"https://secwatch.observer/filing/0001689375-22-000043.md","text":"https://secwatch.observer/filing/0001689375-22-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000043/0001689375-22-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000043/trda-20221107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T05:33:45.217232+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b4d8ae338285a5625ec14d5634b3f00de75219be","claim":"Entrada Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income Net loss for the third quarter of 2022 was $25.1 million.","evidence_excerpt":"Net loss for the third quarter of 2022 was $25.1 million, compared to $14.4 million for the same period of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000043/0001689375-22-000043-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Net income","value":"Net loss for the third quarter of 2022 was $25.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}